Scholarlink

<p>Transradial intervention (TRI) is increasingly used for EVT in these lesions, and the Misago bare nitinol stent (BNS) is compatible with this approach. However, clinical outcomes of the Misago stent via TRI have not yet been reported. Therefore, we evaluated the 3-year clinical outcomes of the Misago stent via TRI. We demonstrated the retrospective, single-center observational study included 348 aorto-iliac arteries in 255 patients treated between October 2019 and May 2023, with Rutherford classifications ranging from categories 1 to 6. The patients were divided into groups: those treated with other stent types via TFI (<i>n</i> = 231) and those treated with Misago stents (<i>n</i> = 117). Additionally, outcomes of patients treated with Misago stents via TRI (<i>n</i> = 72) were compared to those treated with Misago stents via TFI (<i>n</i> = 45). The primary endpoint was 3-year primary patency, and the secondary endpoints were clinically driven target lesion revascularization (CD-TLR), all-cause mortality, major amputation, cerebral infarction, and procedure-associated complications during hospitalization. The 3-year primary patency rate was not significantly different between the Misago stent and other stents (93.2% versus 91.8%, respectively; <i>P</i> = 0.78). Similarly, the 3-year primary patency rate of the Misago stent via TRI was comparable to that of the Misago stent via TFI (91.7% versus 95.6%, respectively; <i>P</i> = 0.44). The competing risks model with multivariate analysis showed that the Misago stent and TRI were not associated with 3-year TLR (hazard ratio [HR], 0.80; 95% confidence interval [CI],0.24–0.64; <i>P</i> = 0.71 and HR, 1.94; 95% CI,0.47–8.07; <i>P</i> = 0.36, respectively). Dialysis and TSAC II C-D were independent predictors of 3-year TLR (HR, 3.28; 95% CI, 1.50–7.18; <i>P</i> = 0.003 and HR, 2.70; 95% CI, 1.28–5.69; <i>P</i> = 0.009, respectively). The Misago stent via TRI for aorto-iliac arterial disease demonstrated acceptable 3-year clinical outcomes. Dialysis and TSAC II C-D were identified as predictors of 3-year TLR.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Three-year clinical outcomes of the Misago stent via transradial intervention for aorto-iliac arterial disease

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月1日

查看全文
  • Yasuyuki Tsuchida,
  • Naoki Hayakawa,
  • Hiromi Miwa,
  • Shinya Ichihara,
  • Shunsuke Maruta,
  • Shunichi Kushida

摘要

Transradial intervention (TRI) is increasingly used for EVT in these lesions, and the Misago bare nitinol stent (BNS) is compatible with this approach. However, clinical outcomes of the Misago stent via TRI have not yet been reported. Therefore, we evaluated the 3-year clinical outcomes of the Misago stent via TRI. We demonstrated the retrospective, single-center observational study included 348 aorto-iliac arteries in 255 patients treated between October 2019 and May 2023, with Rutherford classifications ranging from categories 1 to 6. The patients were divided into groups: those treated with other stent types via TFI (n = 231) and those treated with Misago stents (n = 117). Additionally, outcomes of patients treated with Misago stents via TRI (n = 72) were compared to those treated with Misago stents via TFI (n = 45). The primary endpoint was 3-year primary patency, and the secondary endpoints were clinically driven target lesion revascularization (CD-TLR), all-cause mortality, major amputation, cerebral infarction, and procedure-associated complications during hospitalization. The 3-year primary patency rate was not significantly different between the Misago stent and other stents (93.2% versus 91.8%, respectively; P = 0.78). Similarly, the 3-year primary patency rate of the Misago stent via TRI was comparable to that of the Misago stent via TFI (91.7% versus 95.6%, respectively; P = 0.44). The competing risks model with multivariate analysis showed that the Misago stent and TRI were not associated with 3-year TLR (hazard ratio [HR], 0.80; 95% confidence interval [CI],0.24–0.64; P = 0.71 and HR, 1.94; 95% CI,0.47–8.07; P = 0.36, respectively). Dialysis and TSAC II C-D were independent predictors of 3-year TLR (HR, 3.28; 95% CI, 1.50–7.18; P = 0.003 and HR, 2.70; 95% CI, 1.28–5.69; P = 0.009, respectively). The Misago stent via TRI for aorto-iliac arterial disease demonstrated acceptable 3-year clinical outcomes. Dialysis and TSAC II C-D were identified as predictors of 3-year TLR.